235 related articles for article (PubMed ID: 34098075)
1. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study.
Jiménez-Romero C; Justo I; Marcacuzco A; García V; Manrique A; García-Sesma Á; Calvo J; Fernández I; Martín-Arriscado C; Caso Ó
Int J Surg; 2021 Jul; 91():105981. PubMed ID: 34098075
[TBL] [Abstract][Full Text] [Related]
2. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
3. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
[TBL] [Abstract][Full Text] [Related]
4. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
5. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care.
Bohorquez H; Bugeaud E; Bzowej N; Scheuermann J; Hand J; Bruce D; Carmody I; Cohen A; Joshi S; Seal J; Sonnier D; Therapondos G; Girgrah N; Anders S; Loss GE
Liver Transpl; 2021 Apr; 27(4):548-557. PubMed ID: 33098277
[TBL] [Abstract][Full Text] [Related]
6. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Jung J; Kwon JH; Song GW; Tak EY; Kirchner VA; Lee SG
J Gastrointest Surg; 2018 Aug; 22(8):1334-1342. PubMed ID: 29679347
[TBL] [Abstract][Full Text] [Related]
7. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort.
Bernuth S; Grimm D; Vollmar J; Darstein F; Mittler J; Heise M; Hoppe-Lotichius M; Galle PR; Lang H; Zimmermann T
Drug Des Devel Ther; 2017; 11():2131-2138. PubMed ID: 28744104
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
[TBL] [Abstract][Full Text] [Related]
10. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
11. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
Kauffman-Ortega E; Ruiz-Manriquez J; Olivas-Martinez A; Campos-Murguía A; Flores-García NC; Márquez-Guillén E; López-Yáñez S; Sánchez-Ávila F; Toapanta-Yanchapaxi L; Paez-Zayas VM; García-Juárez I
Arch Med Res; 2021 Oct; 52(7):713-718. PubMed ID: 33966917
[TBL] [Abstract][Full Text] [Related]
13. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.
Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM
Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019
[TBL] [Abstract][Full Text] [Related]
14. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
15. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
Ridruejo E; Piñero F; Mendizabal M; Cheinquer H; Wolff FH; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Zuain MGV; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Silva M;
J Med Virol; 2020 Dec; 92(12):3545-3555. PubMed ID: 32749710
[TBL] [Abstract][Full Text] [Related]
16. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis.
Sobotka LA; Mumtaz K; Wellner MR; Kelly SG; Conteh LF; Hanje AJ; Schenk A; El-Hinnawi A; Black S; Washburn K; Pesavento T; Daloul R; Michaels AJ
Ann Hepatol; 2021; 24():100318. PubMed ID: 33515801
[TBL] [Abstract][Full Text] [Related]
19. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Turgeon MK; Shah SA; Delman AM; Tran BV; Agopian VG; Wedd JP; Magliocca JF; Kim A; Cameron A; Olyaei A; Orloff SL; Anderson MP; Kubal CA; Cannon RM; Locke JE; Simpson MA; Akoad ME; Wongjirad CP; Emamaullee J; Moro A; Aucejo F; Feizpour CA; Vagefi PA; Nguyen MH; Esquivel CO; Dhanireddy K; Subramanian V; Chavarriaga A; Kazimi MM; Anderson MS; Sonnenday CJ; Kim SC; Foley DP; Abdouljoud M; Salgia RJ; Moris D; Sudan DL; Ganesh SR; Humar A; Doyle M; Chapman WC; Maithel SK
Ann Surg; 2021 Oct; 274(4):613-620. PubMed ID: 34506316
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.
Ting PS; Hamilton JP; Gurakar A; Urrunaga NH; Ma M; Glorioso J; King E; Toman LP; Wesson R; Garonzik-Wang J; Ottmann S; Philosophe B; Sulkowski M; Cameron AM; Durand CM; Chen PH
Transpl Infect Dis; 2019 Dec; 21(6):e13194. PubMed ID: 31609520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
